Phio Pharmaceuticals Corp. (PHIO)
NASDAQ: PHIO · Real-Time Price · USD
1.900
+0.090 (4.97%)
At close: May 13, 2025, 4:00 PM
1.870
-0.030 (-1.58%)
Pre-market: May 14, 2025, 6:52 AM EDT
Phio Pharmaceuticals Employees
Phio Pharmaceuticals had 5 employees as of December 31, 2024. The number of employees decreased by 4 or -44.44% compared to the previous year.
Employees
5
Change (1Y)
-4
Growth (1Y)
-44.44%
Revenue / Employee
n/a
Profits / Employee
-$1,430,000
Market Cap
9.08M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
PHIO News
- 6 days ago - Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial - Newsfile Corp
- 12 days ago - Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series - Newsfile Corp
- 4 weeks ago - Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort - Newsfile Corp
- 5 weeks ago - Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894 - Newsfile Corp
- 6 weeks ago - Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update - Newsfile Corp
- 2 months ago - American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting - Newsfile Corp
- 2 months ago - Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study - Newsfile Corp
- 2 months ago - Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors - Newsfile Corp